Incyte pancreatic cancer drug combination induces lasting tumor responses

Incyte reported at the European Society for Medical Oncology congress that its targeted drug, INCB161734, produced lasting tumor responses in certain pancreatic cancer patients when combined with chemotherapy, according to STAT News.

STAT News, citing company statements, reported the durable responses occurred in a subset of patients, though the outlet’s coverage, published behind a subscription paywall, did not specify in its available summary the exact response rate, patient count, or duration figures disclosed at the congress.

Pancreatic cancer remains among the most lethal cancers, with most patients facing poor outcomes and limited treatment options after standard chemotherapy regimens fail or stop working. New approaches that extend disease control, particularly ones showing durability rather than brief shrinkage, are closely watched by oncologists and investors because so few therapies have moved the outcome needle for this disease.

The report arrives as part of the broader slate of data presentations at ESMO, where pharmaceutical companies routinely disclose early and mid-stage trial results to oncologists, investors, and journalists gathered at the congress.

STAT News did not detail in its summary the trial’s phase, size, or design, nor did it specify the chemotherapy regimen paired with INCB161734. The outlet attributed the characterization of the responses as “lasting” to company statements made at the congress, rather than to independently published peer-reviewed data.